Breaking News

KalVista Raises $33 Million

Funding will advance development of novel plasma kallikrein inhibitors in diabetic macular edema and hereditary angioedema

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

KalVista Pharmaceuticals, a research-led pharmaceutical company, has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista says it will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE). Alongside the existing investors, Novo A/S and SV Life Sciences, the round included additional international healthcare investors experienced in plas...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters